RxDoctor Payments Data

Ajoe John Kattoor

Interventional Cardiology · la Porte, INNPI 1659754422

Payments from drug & device makers

$12,433in general payments, 2019–2025

Across 249 payments — averaging $49.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$4K
  • Medtronic$3K
  • Abbott$2K
  • Boston Scientific$1K
  • Inari Medical, Inc.$941
  • Amgen$338
  • plus $969 from 11 others

What the payments were for

  • Travel & lodging$4,67438%
  • Food & beverage$7,61461%
  • Education$1451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,433 in reported general payments places this provider in the 60th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$195,102
Medicare patients
682
Services billed
2,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$72,703
EntrestoSacubitril/Valsartan34$49,492
Repatha SureclickEvolocumab24$32,460
XareltoRivaroxaban30$32,047
BrilintaTicagrelor45$29,679
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$3,215
Prasugrel Hcl14$1,985
ClopidogrelClopidogrel Bisulfate199$1,873
Metoprolol Succinate191$1,705
Flecainide Acetate19$1,234
Ezetimibe50$1,149
Atorvastatin Calcium189$1,116
Amiodarone Hcl29$729
Isosorbide Mononitrate ErIsosorbide Mononitrate56$593
Potassium Chloride47$548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$72,70363 claims
NovartisEntresto$34$49,49234 claims
AstraZenecaBrilinta$35$29,67945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in la Porte

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →